Viral hemorrhagic fever

Summary

Viral hemorrhagic fever (MONDO:0018087) is a disease (an umbrella term covering 16 Mondo subtypes) and 8 clinical trials. Top therapeutic interventions include baricitinib. A subtype of viral infectious disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Prevalence: Unknown (Worldwide)
• Umbrella term: 16 Mondo subtypes
• Clinical trials: 8

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	viral hemorrhagic fever
Mondo ID	MONDO:0018087
MeSH	D006482
Orphanet	341
NCIT	C36170
SNOMED CT	240523007
UMLS	C0019104
MedGen	9213
GARD	0005494
Is cancer (heuristic)	no

Also known as: haemorrhagic fever · haemorrhagic fevers, viral · hemorrhagic fever · hemorrhagic fevers · VHF · VHFs · viral haemorrhagic fever

Disease family

This is a subtype of viral infectious disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › viral infectious disease › viral hemorrhagic fever

Related subtypes (40): Whitewater Arroyo hemorrhagic fever, exanthema subitum, Zika virus congenital syndrome, common wart, viral labyrinthitis, viral gastritis, vaccinia, viral esophagitis, Kaposi’s sarcoma, contagious pustular dermatitis, epidemic pleurodynia, herpangina, human T-lymphotropic virus 1 infectious disease, lumpy skin disease, milker’s nodule, molluscum contagiosum, Newcastle disease, pharyngoconjunctival fever, pseudorabies, Reoviridae infectious disease, immunodeficiency 32B, focal epithelial hyperplasia, neurolymphomatosis, viral myositis, virus-associated trichodysplasia spinulosa, infective dermatitis associated with HTLV-1, congenital varicella syndrome, arbovirus fever, human infection by orthopoxvirus, congenital Epstein-Barr virus infection, rabies, arbovirus infection, viral eye infection, viral infection of central nervous system, viral respiratory tract infection, Parvoviridae infectious disease, COVID-19–associated multisystem inflammatory syndrome in children, primary viral infectious disease, disease arising from reactivation of latent virus, human betaherpesvirus 5 infectious disease

Subtypes (16): Dengue hemorrhagic fever, arenavirus hemorrhagic fever, Ebola hemorrhagic fever, Venezuelan equine encephalitis, Lujo hemorrhagic fever, Bolivian hemorrhagic fever, Venezuelan hemorrhagic fever, Brazilian hemorrhagic fever, Chapare hemorrhagic fever, hantavirus pulmonary syndrome, Rift valley fever, Kyasanur forest disease, Omsk hemorrhagic fever, hemorrhagic fever-renal syndrome, Marburg hemorrhagic fever, Crimean-Congo hemorrhagic fever

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 8.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	3
PHASE2	2
PHASE1	2
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT07543458	PHASE3	NOT_YET_RECRUITING	Therapeutics for Moderate and Severe Dengue
NCT04283513	PHASE2	ACTIVE_NOT_RECRUITING	Treatment of Hemorrhagic Fever With Ribavirin
NCT01973855	PHASE2	UNKNOWN	Chinese and Western Medicine Treatment of Fever Associated With Bleeding Symptoms
NCT02267109	PHASE1	COMPLETED	Phase 1 Trial of Ebola Vaccine in Mali
NCT02368119	PHASE1	COMPLETED	Ebola CVD-Mali #2000 (Bivalent) VRC-EBOAdc069-00-vp (cAd3-EBO)
NCT02483260	Not specified	ENROLLING_BY_INVITATION	Intravenous Ribavirin Protocol to Treat Individuals With Viral Hemorrhagic Fever
NCT07370454	Not specified	COMPLETED	Xpert® Hemorrhagic Fever on the GeneXpert® Edge X System
NCT07591740	Not specified	COMPLETED	Xpert Hemorrhagic Fever on Edge X in Trained and Untrained Users

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
BARICITINIB	4	1
CHEMBL5427854	0	1
CHEMBL5435500	0	1